Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-33

Considering major BP have reviewed the abstract & typically takeovers follow convincing data post ASH conferences, a transaction of some kind could happen a lot sooner than some of us think.

We know Abbvie, BMS, and others were at the table and in discussions around cardio/breast cancer programs prior to DCB departure, now they’ve just reviewed AML synergies with absent toxicity.

If they could put 2+2 together as well as Mason can and draw correlation to FTO inhibition being the reason this combo was effective, I can’t see how they wouldn’t be writing up the paper work now. Why wait until Dec when there’s more eyes & competition.